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Abstract
In lead discovery, libraries of 106 molecules are screened for biological activity. Given the over 
1060 drug-like molecules thought possible, such screens might never succeed. That they do, even 
occasionally, implies a biased selection of library molecules. Here a method is developed to 
quantify the bias in screening libraries towards biogenic molecules. With this approach, we 
consider what is missing from screening libraries and how they can be optimized.
High-throughput screening (HTS) is the dominant method of lead discovery in 
pharmaceutical research and chemical biology. A plurality of the new chemical entities in 
clinical trials may have their origins in this technique, as do at least two drug.1 Whereas 
these screens have been productive against traditional drug targets, such as GPCRs, ligand-
gated ion channels, and kinases, screening libraries of synthetic molecules has been 
problematic for others, such as antimicrobial targets and those identified from genomic 
studies. The reasons for these successes and failures have been widely debated.2-5 From a 
theoretical perspective, however, one might wonder not that screens of 106 molecules 
sometimes fail, but rather that they ever succeed.
Chemical space, i.e. all possible molecules, is estimated to be greater than 1060 molecules 
with 30 or fewer heavy atoms;6 10μg of each would exceed the mass of the observable 
universe. This figure will diminish if criteria for synthetic accessibility and drug-likeness are 
taken into account and increase steeply if up to 35 heavy atoms, about 500 Daltons, are 
allowed. Positing even a modest specificity of proteins for their ligand, the odds of a hit in a 
random selection of 106 molecules from this space seems negligible.
HTS nevertheless does return active molecules for many targets; how does it overcome the 
odds stacked against it? One might hazard two hypotheses. First, molecules that are formally 
chemically different can be degenerate to a target, and many derivatives of a chemotype may 
have little effect on affinity. This behavior, and the polypharmacology of small molecules,
7-9 undoubtedly contributes to screening hit rates. Such chemical degeneracy seems 
unlikely, however, to overcome the long odds against screening. A second explanation is 
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that screening libraries are far from random selections, but rather are biased toward 
molecules likely to be recognized by biological targets. This second hypothesis seems more 
plausible, as many accessible molecules are likely to resemble or derive from metabolites 
and natural products. Some of these will have been synthesized to resemble such biogenic 
molecules, while others will have used biogenic molecules as a starting material. The role of 
bias in screening has been mooted before,10-13 and indeed methods to measure metabolite- 
or natural product-likeness have been reported, permitting the design of these features into 
screening libraries.14,15 How such bias might be quantified relative to what one would 
expect for an unbiased collection, and thus its extent and impact on screening and discovery, 
has remained unexplored.
Quantifying library bias requires three sets of molecules: one that represents all of chemical 
space, one that represents molecules that proteins are intrinsically likely to recognize—
defining the optimal bias, and one that represents screening libraries. The set representing 
chemical space previously seemed inaccessible. Recently, however, Fink and Reymond have 
calculated all of the synthetically accessible molecules with 11 or fewer non-hydrogen 
(heavy) atoms composed of first row elements (C, N, O, and F); there are over 26 million of 
these, not allowing for stereochemistry.16 Whereas these molecules are small compared to 
most biologically interesting compounds, this Generated DataBase (GDB) is comprehensive, 
giving us the full unbiased set within its boundary criteria. For the molecules that proteins 
are likely to bind—defining the bias—several sets are possible, such as those molecules that 
have become drugs. Indeed, several investigators have adopted this approach when asking 
“what is drug-likeness and how can libraries be biased towards it?”17,18 Here, however, we 
ask why one should expect to find any hits from screening, and so need a reference set that 
captures protein recognition in general. For this purpose drugs are imperfect, reflecting 
many other criteria, like bioavailability, and are backward-looking, capturing information 
only on a small number of targets. We therefore chose metabolites and natural products from 
the KEGG (2 018 molecules) and the Dictionary of Natural Products (141 985 molecules) 
databases, respectively. These molecules are recognized by at least one protein in the 
biosphere, often many, and are out-group molecules, uninfluenced by human invention. For 
the set of molecules representing screening libraries we use those molecules that are 
commercially available, reasoning that most HTS libraries, even in the pharmaceutical 
industry, are largely composed of molecules that have been purchased from commercial 
vendors, or closely resemble them (for the MLSMR, the US national screening collection, 
almost all of the ∼300 000 molecules are commercially sourced). To compare the 
commercially available molecules to those of the GDB, we restrict the former by the same 
criteria: only purchasable molecules with 11 or fewer heavy atoms composed of first row 
elements are considered. There are 25 810 such molecules in the ZINC database of 
commercially available molecules (http://zinc.docking.org); we refer to these as the 
purchasable-GDB (Fig. 1).
As we will show, when metabolites are compared to both the purchasable-GDB and the full 
GDB, the purchasable subset is almost 1000-fold more similar to metabolites than the 
overall GDB, our proxy to full chemical space. The same bias is observed when the two sets 
are compared to natural products. The bias grows dramatically with molecular size, 
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suggesting that this bias will be greater still among larger “lead-like” or “drug-like” 
molecules in screening. This is consistent with the idea that these libraries are massively and 
productively biased toward biogenic molecules. We leverage this observation to ask what 
scaffolds occur among biogenic molecules but are absent from those commercially 
available. Almost 1300 ring-scaffolds are found among natural products that are missing 
from commercial libraries—these scaffolds provide criteria that could be used to further 
increase the bias in screening libraries toward those molecules that proteins have evolved to 
recognize.
RESULTS
We first compared the 26 million GDB and the 25 810 purchasable-GDB molecules to the 
metabolites and the natural products. With the widely used ECFP_4 topological 
fingerprints19 we calculated the similarity between each biogenic molecule and each GDB 
and purchasable-GDB molecule. We plotted the percentage of GDB and purchasable-GDB 
molecules that had at least one metabolite or, separately, one natural product within a certain 
similarity, expressed as Tanimoto score (where a similarity score of 1 indicates identity 
between the pair of molecules and a similarity score of 0.2 indicates a similarity so low as to 
be essentially meaningless). As expected, almost all GDB and purchasable-GDB molecules 
had a similarity coefficient of 0.2 or greater to at least one metabolite or natural product 
(Fig. 2a,b, and Supplementary Figs. 1a,b, and 2a,b online). After this plateau, the 
percentages decreased rapidly as the similarity threshold became more stringent. Critically, 
it diminished orders of magnitude faster for the GDB than it did for the purchasable subset 
of GDB. Even by a similarity coefficient of 0.32 there were tenfold more molecules from the 
purchasable-GDB, expressed as a percentage, than GDB molecules that resembled at least 
one metabolite. By a similarity coefficient of 0.53 this ratio was 100-fold and by the time 
full identity was reached, considering only exact biogenic molecules in the purchasable 
subset of the GDB, 0.83% (215 compounds) and 10.5% (2703 compounds) of the 25 810 
purchasable GDB molecules were identical to metabolites and natural products, respectively
—an enrichment of 922-fold and 618-fold compared to the full GDB. Since there are 1000-
fold more GDB than purchasable-GDB molecules this ratio implies that most of the natural 
products or metabolites represented in the 26 million compounds of the GDB are captured 
by the 25 810 molecule subset that has actually been synthesized and may be purchased. 
This bias was unaffected by the size of the molecules used in the reference databases, and 
was the same whether we used the full set of metabolites and natural products or only those 
compliant with the GDB rules (Supplementary. Fig 3 online). A bias towards metabolites 
and natural products of similar magnitude was also found among commercially-available 
compound sets specifically designed for screening (Fig. 2c,d), while for the US National 
MLSMR library the molecules subject to the GDB restrictions (MLSMR-GDB) were even 
more biased toward metabolites and natural products (Fig. 2c,d). In all libraries this bias 
increases exponentially with molecular size (Fig 3a,b>) and so we expect that most 
screening collections, made up of larger molecules than considered here, will be even orders 
of magnitude more biased towards biogenic molecules.
We investigated if there were particular chemical features that were most responsible for this 
bias. Whereas we do not pretend to undertake a comprehensive analysis of particular 
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chemotypes here, a preliminary study may interest some investigators. We identified 871 
bits from unfolded fingerprints that occurred in more than 1% of the metabolites or the 
natural products (there were 174 823 different bits among these molecules before folding). 
28 of those bits (functional groups) also occurred in more than 0.5% of the purchasable-
GDB database and in less than 0.05% of the GDB database, representing at least a ten-fold 
bias of the purchasable-GDB relative to the entire GDB. The substructures corresponding to 
these bits illustrate some of the fragments contributing to the observed bias (Supplementary 
Table 1 online). For instance, meta-substituted aryl alcohols, such as 3-methylphenol, occur 
among 1.3% of metabolites, 2.2% of natural products and 0.6% of the purchasable-GDB, 
but only in 0.006% of the entire GDB. As an aside, notwithstanding the much greater 
similarity of the purchasable-GDB to metabolites and natural products than the overall 
GDB, some functional groups were actually under-represented among the purchasable-
GDB. Thus, 38 bits occurred in more than 0.5% of the GDB and more than 1% of 
metabolites or natural products but in less than 0.2% of the purchasable-GDB 
(Supplementary Table 2 online). For instance, 1,2-trisubstituted epoxides occur in 2.6% of 
natural products and 1.7% of the GDB but in only 0.01% of the purchasable-GDB. Were 
such substructures included in future commercial compounds they would increase the 
already substantial bias still further.
If it is true that bias towards biogenic molecules contributes to the success of screening, it 
seems interesting to ask whether this bias might be increased, productively, by adding 
scaffolds present among biogenic molecules that are currently unexplored in our libraries. 
We again turned to the metabolites, natural products, and commercially available molecules, 
this time considering each without limit to molecular size or composition. To find scaffolds 
present among the two biogenic sets but absent from the commercially available molecules, 
we represented the molecules by their core rings (Supplementary Fig. 4 online).20 Each core 
ring scaffold among the biogenic molecules was matched to its counterpart among 
commercially available molecules, when available. There were 173, 15 637 and 29 496 
unique rings among the 2 018 metabolites, 141 985 natural products and 9 131 254 
commercially available molecules, respectively. 34 (20%) of the ring scaffolds among the 
metabolites and 12 977 (83%) of the ring scaffolds among the natural products were 
unrepresented among the commercial molecules. Even if one restricts this set to molecular 
weight ≤350 Da and two or fewer stereocenters, there remain 1 891 ring scaffolds 
represented among natural products that have no counterpart among commercially available 
molecules, and by extension screening libraries.
DISCUSSION
Returning to our motivating question, a major reason why the screening of synthetic 
compounds ever finds interesting hits is that our libraries are biased towards the sort of 
molecules that proteins have evolved to recognize. Thus, there are almost as many 
metabolites and natural products among the 25 810 purchasable GDB molecules as there are 
among the 26 million GDB molecules overall. This bias increases rapidly as molecules grow 
in size (Fig. 3), and the bias among larger “lead-like” and “drug-like” molecules is expected 
to be many orders of magnitude more still than that measured for the very small molecules 
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explored here, where full enumeration16 allowed us to compare to a complete chemical 
space.
From this observation two opposite inferences might be drawn. Since our libraries are 
already biased, then perhaps we should look for new screening molecules that are dissimilar 
to metabolites and natural products. Whereas this will certainly explore new chemotypes and 
ensure novel scaffolds, we do not draw this conclusion. Chemical space is so large that, 
unless proteins are highly promiscuous, the likelihood of finding anything biologically 
interesting is remote. Instead, we suggest that screening libraries may be improved by 
increasing the bias toward biogenic molecules further still, by adding to libraries molecules 
resembling biogenic scaffolds that are now absent from them. After all, the bias in our 
current libraries is largely unintentional, the product of what organic chemists have 
synthesized since the birth of the field with urea in 1828 (though see refs 21-24). This leaves 
room for intentional optimization. Indeed, 83% of the core ring-scaffolds present among 
natural products are simply absent among commercially available molecules, and by 
extension screening libraries.
It is interesting to compare these missing scaffolds with those from earlier studies that 
sought rings most common among drug-like molecules.20,25-27 An example are the six 
rings highlighted as characteristic of drug-like molecules by Ertl and colleagues (Table 1). 
Comparing these to those scaffolds found among natural products but unavailable 
commercially reveals molecules that are so similar to the drug-like rings that their absence 
from screening libraries is startling (a few examples are given in Table 2). Earlier studies 
have suggested that scaffolds characteristic of drug-like molecules be sought when 
purchasing new molecules for screening; here we suggest that molecules containing 
scaffolds present in natural products but absent from commercial collections are places to 
begin expanding the biogenic chemistry available for screening. Biasing future screening 
libraries to fill these systematic absences in our current collections will help address the new 
genomic targets with which we are increasingly confronted, and against which screening has 
had such mixed success.
METHODS
Chemical Space
We used the Generated DataBase (GDB) of Reymond et al. as a proxy for chemical space.
16,28 The GDB was obtained by exhaustively enumerating all the possible topologies for 
molecules composed of only first row elements (C, N, O, and F), taking into account the 
stability, synthetic accessibility, and drug likeness of the resulting molecules. GDB 
contained 26 429 328 unique compounds with no consideration of stereochemistry.
Biogenic Space
We used two databases to approximate the space of molecules that occur in natural 
organisms: the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and the 
Dictionary of Natural Products (DNP). The KEGG (Ligand) database contained 11 434 
unique compounds,29 but many of these were xenobiotics such as hexachlorohexane. A 
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xenobiotic-free subset of the KEGG database was generated by only considering primary 
metabolic pathways (Supplementary Table 3). This subset contained 2 018 unique 
compounds and was used as the reference to metabolic space. The CRC Dictionary of 
Natural Products30 (DNP version 16.2) contained 141 985 unique structures and was used 
as the source of natural products.
Screening library space
ZINC31 contains 9 131 254 unique, commercially available compounds after adding the 
latest vendor catalogs and discarding some of the physical property filters normally used for 
docking purposes, such as molecular weight. ZINC was used as an approximation to a 
general-purpose screening library. To compare commercial compounds to the GDB, we 
filtered ZINC for molecules that conformed to the same rules as those used to generate the 
GDB. ZINC contained 25 810 compounds with 11 or less C, N, O, or F atoms, the 
“purchasable-GDB.”
The National Institute of Health (NIH) Molecular Libraries Small Molecule Repository 
(MLSMR) contained 298 794 unique compounds (downloaded from http://
pubchem.ncbi.nlm.nih.gov on 2008/06/18). The MLSMR contained 866 compounds with 11 
or less C, N, O, and F heavy atoms, i.e. subject to the same restrictions as GDB. This subset 
was referred to as MLSMR-GDB.
Comparison of the chemical and screening space to the biogenic spaces
Each molecule of the GDB and purchasable-GDB databases was, in turn, compared to each 
molecule in the KEGG and DNP databases. Compounds were represented by their Scitegic 
Extended Connectivity FingerPrints32 (ECFP_4) which encodes the presence or absence of 
topological fragments (with no stereochemistry consideration) in the form of an extended 
connectivity string centered on a specific atom and calculated using a modification of the 
Morgan Algorithm.33 The initial code assigned to each molecule's atom is based on the 
number of connections, the element type, and the mass. This code is hashed to produce the 
next order code, which is mapped into an address space of size 232 and the process iterates 
twice to describe features up to four bonds in diameter.34 The resulting fingerprint was 
further folded into a bit-string of length 1 024 bits. The similarity between two molecules 
was measured by comparing their respective ECFP_4 bit-string with the Tanimoto 
coefficient. If a denotes the number of bits set to “on” for molecule A, b the number of bits 
set to “on” for molecule B, and c the number of bits set to “on” in both molecules, the 
Tanimoto similarity between these two molecules is:
Analysis of the bit frequencies
Each bit's exact substructure was exported as a SMARTS pattern (before folding) using the 
built-in function of the standard molecular fingerprint component of Scitegic Pipeline Pilot.
32 There were cases where a single bit corresponded to more than one substructure; often 
these substructures were related. For the frequency calculations or even for illustration 
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purposes (see Supplementary Tables 1 and 2 online), one of these substructure was chosen 
arbitrarily.
Generation of the core ring scaffolds
Several approaches to extract the scaffold of a molecule are available;20,26,35 here we use 
the approach of Bemis & Murcko.20 Each molecule in the KEGG, DNP, and ZINC 
databases was decomposed into its core ring scaffold using Pipeline Pilot.32 Core ring 
scaffolds consist of individual contiguous ring systems keeping atom types, bond orders, 
aromaticity information, and exocyclic double bonds but discarding stereochemistry and 
charges (see Supplementary. Fig. 4 online). A canonical SMILES string was generated for 
each resulting core ring structure. The presence (or absence) of a particular KEGG or DNP 
scaffold was evaluated by matching its SMILES string to those obtained from the ZINC 
database.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Overlap between commercially available molecules and the GDB gives the purchasable 
GDB.
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Figure 2. Compounds in screening libraries are biased toward biogenic molecules
Percentage of the GDB and purchasable-GDB databases as a function of the Tanimoto 
similarity to their nearest neighbor in [a] the KEGG and [b] the Dictionary of Natural 
Compound databases. Percentage of the GDB, the purchasable-GDB, Asinex (360 042 
compounds − 815 GDB compliant compounds), Chembridge (473 745 compounds − 389 
GDB compliant compounds); IBS (424 806 compounds − 884 GDB compliant compounds), 
Life Chemicals (285 581 compounds − 172 GDB compliant compounds), Otava (121 657 
compounds − 287 GDB compliant compounds) databases as a function of the Tanimoto 
similarity to their nearest neighbor to the [c] KEGG and the [d] Dictionary of Natural 
Products databases.
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Figure 3. 
Ratio of the percentage of compounds in the purchasable-GDB and GDB databases that had 
a similarity ≥ 0.75 to their nearest neighbor in [a] the KEGG and [b] the Dictionary of 
Natural Products databases versus the number of heavy atoms up to which the database 
compound (in purchasable-GDB and GDB) are considered.
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Table 1
Core ring structures common among drugs and related molecules.25
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Table 2
Characteristic scaffolds present among natural products but missing from commercially available molecules. 
The core ring scaffold is shown in green for the natural products.
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